GVHD and toxicity
aGVHD, GVHD
ADVERSE EVENTS, GVHD, ACUTE GRAFT-VERSUS-HOST DISEASE
In this study, patients not achieving CR received more intensive chemotherapy and higher-dose DLIs. It has been shown that strong chemotherapy and repeated DLIs in a short time result in GVHD. Therefore, when we assessed aGVHD, we included 13 patients who only received the CCAG plus DLI regimen within several months. The cumulative incidence of grade II–IV aGVHD was 33.5%, with only 9.4% of patients having grade III–IV aGVHD (Fig aGVHD of 13 participants who only accepted CCAG plus DLI regimen in a short time. The rate of grade II–IV aGVHD: 33.5; 95% CI, 10–59.5%. The rate of grade III–IV aGVHD: 9.4%; 95% CI, 0.6–34.2%. aGVHD: acute graft-versus-host disease; AEs considered to be related to CCAG plus DLI regimen are shown in Table Common adverse events of all participants